Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon5.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-PRKCD, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Protein kinase C delta (PKC delta) often called PKCδ belongs to the novel PKC subfamily. It weighs approximately 78 kDa and functions in various cellular processes. This enzyme exhibits serine/threonine kinase activity and is expressed across numerous tissues including the brain heart and lymphoid organs. PKC delta activation mainly relies on diacylglycerol and phospholipids though it does not require calcium for activation. This target has multiple known phosphorylation sites such as delta 1485 and delta 647 that modulate its enzymatic activity and localization.
Biological function summary
PKC delta influences cell growth apoptosis and differentiation through its kinase activity. It acts as an important regulator in the signaling pathways that control these processes. PKC delta is not a part of a traditional complex but interacts with several proteins influencing signaling cascades. In cellular contexts PKC delta positively influences tumor necrosis factor-related pathways and also initiates apoptosis in response to DNA damage.
Pathways
PKC delta plays an essential role in the regulation of mitogen-activated protein kinase (MAPK) and Janus kinase (JAK) pathways. Within the MAPK pathway PKC delta interacts with proteins like c-Jun N-terminal kinase (JNK) facilitating stress-responsive pathways related to cell death and survival. In the JAK pathway its regulation can impact cytokine signaling and immune responses. PKC delta's function within these pathways positions it as an important mediator and influencer of diverse cellular responses.
PKC delta has significant implications for cancer and cardiovascular diseases. PKC delta promotes tumor cell proliferation in some cancers by altering cell cycle regulation and resist apoptosis. In cardiovascular disorders this protein mediates cardiac hypertrophy and heart failure through its influence on myocyte apoptosis and fibrosis. PKC delta’s interaction with specific proteins like Bcl-2 in cancer and troponin in cardiac conditions highlights its role in pathophysiological processes making it a significant target for therapeutic intervention.
